BIOCONPharmaceuticals
Biocon Ltd — PE Ratio & Valuation Analysis
₹360.90
-2.52%
Current P/E111.20xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E50.5x120.0% above avg
⚠️
250.0% Premium to Industry
BIOCON P/E 111.20x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹8.46 | ₹394 | 46.6x |
| 2024 | ₹8.54 | ₹365 | 42.8x |
| 2023 | ₹3.87 | ₹250 | 64.5x |
| 2022 | ₹5.42 | ₹262 | 48.3x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Biocon Ltd Valuation
Biocon Ltd (BIOCON) currently trades at 111.20x earnings. The Pharmaceuticals sector average PE is 31.77x. BIOCON commands a premium, reflecting high growth expectations. Historically, BIOCON has traded at an average PE of 50.5x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
4.76%
Dividend Yield
0.13%
More on Biocon Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.